IMMUNO-ONCOLOGY

免疫肿瘤学

• 批准号: 7506791
• 负责人: MATTHEW D SCHARFF
• 金额: $ 2.65万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-25 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7506791
• 关键词: Albert Einstein Cancer Center; Antigens; B-Cell Lymphomas; Cancer Center Support Grant; Cancer Vaccines; Cervical; Clinical; Clinical Research; Clinical Trials; Collaborations; Community Clinical Oncology Program; Defect; Development; Evolution; Faculty; Generation of Antibody Diversity; Genomic Instability; Goals; Grant; Immunoglobulin Genes; Immunotherapy; Lead; Link; Lymphoma; Malignant Neoplasms; Melanins; Mutation; Neoplasms; Paper; Pathogenesis; Peptides; Pharmacologic Substance; Physicians; Preparation; Process; Proteins; Radio; Radioisotopes; Rate; Research; Research Personnel; Role; Scientist; Solid Neoplasm; T-Lymphocyte; Therapeutic; Time; United States National Institutes of Health; Vaccines; Variant; Viral; college; immunogenicity; inhibitor/antagonist; large cell Diffuse non-Hodgkin' s lymphoma; member; oncology; prevent; programs; response; therapeutic target; tumor

The Immuno-oncology Program has traditionally represented a major focus of basic scientific strength at AECC and at the last CCSG review was rated as excellent. Since that time this program has greatly increased its cancer focus through changes in membership, the evolution of research of existing members and the recruitment of new faculty, several of whom are physician-scientists, to the College and this Program. These changes were a natural evolution program member's research and a response to the previous summary statement. The goals of the Immuno-oncology program are: 1) To determine how defects in the targeting of the genomic instability of immunoglobulin genes required for the generation of antibody diversity lead to the mutations and translocations that cause B cell lymphomas and to search for ways to prevent such errors. One objective is to develop therapeutics targeted specifically to molecularly distinct Bcell lymphoma variants. 2) To better understand how antigen is presented to T cells and how to manipulate that process to increase the immunogenicity of tumors and cancer vaccines. 3) To develop and apply new immune therapies with a focus on radio-immunotherapy and vaccines to viral-induced tumors. Translational accomplishments include the development of a anti-melanin-mAb-radionuclide therapeutic, which emerged from studies on fungal melanin, that will enter clinical trials in 2007. Studies focused on the role of Bcl6 in the pathogenesis of diffuse large B cell lymphoma have identified a peptide inhibitor of the interaction between this protein and its corepressor. This peptide is active pre-clinically, and is being further developed in preparation for transition to a pharmaceutical company for clinical studies. The recruitment of two secondary members to this program has linked clinical and basic investigators who study vaccines within the context of clinical trials focused on the treatment of cervical neoplasia and other solid tumors. There are currently 16 program members from 11 departments, of whom 11 are primary members, supported by 6 NCI ($1.45M Direct) and 7 other NIH grants. Since the last CCSG review there have been 176 cancer-relevant research papers by members of this program of which 7% represent intraprogrammatic, and 19% represent interprogrammatic collaborations.

传统上，免疫肿瘤学计划代表了基本科学实力的主要重点 AECC和最后一次CCSG评论被评为出色。从那时起，这个程序有很大的 通过变化，现有成员研究的发展来增加其癌症的关注 新教师的招募，其中几个是医师科学家到大学，这是 程序。这些变化是自然进化计划成员的研究，以及对 先前的摘要声明。免疫肿瘤学计划的目标是：1）确定缺陷 在靶向产生抗体所需的免疫球蛋白基因的基因组不稳定性中 多样性导致引起B细胞淋巴瘤的突变和易位，并寻找方法 防止此类错误。一个目的是开发专门针对分子不同BCELL的治疗剂 淋巴瘤变体。 2）更好地了解如何将抗原呈现给T细胞以及如何操纵 增加肿瘤和癌症疫苗的免疫原性的过程。 3）开发和应用新的 免疫疗法专注于放射免疫疗法和疫苗对病毒诱导的肿瘤。翻译 成就包括发展出现的抗黑素蛋白-MAB-Radionuclide疗法，并出现 从2007年将进入临床试验的真菌黑色素的研究中。研究重点是Bcl6在 弥漫性大B细胞淋巴瘤的发病机理已确定了肽抑制剂的相互作用 该蛋白质及其核心蛋白。该肽在临时活动中是活跃的，正在进一步开发 准备过渡到制药公司进行临床研究。招募两个次要 该计划的成员已将研究疫苗研究的临床和基本研究人员联系在一起 临床试验的重点是治疗宫颈肿瘤和其他实体瘤。目前有16个 来自11个部门的计划成员，其中11个是主要成员，由6个NCI支持（145万美元 直接）和其他7个NIH赠款。自上次CCSG评论以来，已经进行了176项与癌症有关的研究 该计划成员的论文，其中7％代表插图内图，19％代表 解释性合作。